Bacteremia Clinical Trial
Official title:
Turkish Prospective Cohort Study on Carbapenem Resistant Klebsiella Pneumonia Bacteremia: a National Multicenter Observational Study
Carbapenem-resistant Klebsiella pneumonia (CRKp) blood stream infections (BSI) cause substantial mortality among hospitalized patients. Treatment options for CRKp infections are limited and increasing resistance rates to few available drugs, i.e., colistin, is a big concern. This prospective multicenter observational study is designed to describe clinical characteristics and outcomes of patients with CRKp bacteremia in an oxacillinase-48 (OXA-48) endemic country to define predictors of mortality with a focus on the impact of mono versus combination therapies on mortality. The study will also investigate risk factors associated with colistin-resistant CRKp BSI.
OBJECTIVES
MAIN OBJECTIVE
1. To compare the impact of combination therapy and monotherapy on mortality for patients
with CRKp BSI
SECONDARY OBJECTIVES
2. To identify predictors of mortality for patients with CRKp BSI
3. To compare the impact of appropriate and inappropriate empiric and targeted therapies on
mortality for patients with CRKp BSI
4. To identify the risk factors for colistin resistance among patients with ColR CRKp BSI.
HYPOTHESES
MAIN HYPOTHESIS
1. Combination therapy is better than monotherapy to prevent 30-day mortality.
i.Combination of one active drug with one inactive drug is not associated with lower
probability of mortality as compared to monotherapy with one active drug if:
- the inactive drug is carbapenem with a minimum inhibitory concentration (MIC) of
≥16 mg/L or
- the inactive drug is any other antibiotic other than carbapenem or
- the patient is in low mortality score
ii.Combination of two or more active drugs is associated with lower probability of
mortality as compared to monotherapy with one active drug.
iii.For colistin resistant CRKp, monotherapy with one active drug is associated with
lower probability of mortality as compared to combination therapies including carbapenem
with a MIC of ≥16 mg/L or colistin.
SECONDARY HYPOTHESES
2. Severe disease at BSI onset (admission to ICU, septic shock, INCREMENT-CPE
(carbapenemase-producing Enterobacteriaceae) score 8-15, higher sequential organ failure
assessment (SOFA) and Pitt bacteremia scores, Charlson Comorbidity Index ≥2, higher
procalcitonin levels), carbapenemase type and carbapenem MIC of the isolate (CRKp
isolates with a carbapenem MIC ≥16 mg/L, OXA-48 producing isolates), sequence type of
the isolate (ST101 and ST258), colistin resistance delayed source control (>48 hours)
and infection sources other than urinary tract are independent predictors of mortality.
3. Appropriate empirical therapy, early targeted therapy, are independent predictors of
survival. For colistin susceptible CRKp, empirical use of colistin within 24 hours of
BSI onset is associated with lower probability of mortality.
4. Previous colistin therapy, previous CRKp infection, previous intensive care unit (ICU)
stay (last three months), length of hospital stay until index date is associated with
colistin resistance. Mortality rates and length of hospital stay are higher among
colistin resistant strains as compared to colistin susceptible strains.
5. Effect of treatment type on mortality is modified by disease severity.
STUDY DESIGN
Prospective cohort study.
Setting and study period
Fourteen tertiary care hospitals from the four most populous cities in Turkey (Istanbul,
Ankara, Izmir, Bursa) are included in the study. Study period is scheduled to be 25 June
2018- 25 June 2019 or longer until pre-defined sample size is reached. Local investigators
(infectious disease physicians and clinical microbiologists) will collect microbiological and
clinical data. Site investigators will screen the microbiology laboratory logs daily to
identify patients with CRKp bacteremia. All consecutive patients with CRKp bacteremia will be
eligible to be evaluated for inclusion in the study. Patients who meet the inclusion criteria
will be selected for the prospective cohort study and/or case-control study depending on
colistin resistance pattern of the isolate. Site investigators will access patients' medical
records and register relevant information using a web-based data entry system. Site
investigators will also collect CRKp isolates and keep them in appropriate conditions until
time of transfer for analysis. All CRKp isolates will be sent to the central microbiology
laboratory for molecular analysis and colistin and ceftazidime-avibactam sensitivity testing.
Sample size
The expected mortality rate for CRKp BSI is approximately 40% based on previous studies (7,
12) To detect a 17% decrease in mortality rate with combination therapy as compared to
monotherapy, we calculated an overall sample size of 178 (α=0.05, power=0.8) (STATA 15.0,
power analysis for the cox proportional hazards model) (7). Considering withdrawals and
incomplete data, we aimed to recruit 200 patients.
Given that we were able to recruit patients faster than expected within our study period (25
June 2018- 25 June 2019), we decided to increase our power to 0.9.
Follow up
Patients will be evaluated for microbiologic eradication on day 3 by control blood cultures
and primary source cultures. If CRKp is not eradicated on day 3, consecutive cultures will be
taken on day 7 and 14, as required. Patients will also be evaluated for clinical response on
day 7 and day 14 using 7th and 14th day SOFA scores, C-reactive protein, procalcitonin and
leucocyte levels and clinical signs of infection. All patients will be followed for 30 days
after index date. If the patient is discharged before completion of the 30 days, he/she will
be contacted by phone on day 30 to assess the outcome.
DEFINITIONS
CRKp: K. pneumonia non-susceptible to at least one carbapenem according to EUCAST 2018
breakpoints.
Colistin-resistant (ColR) CRKp: CRKp resistant to colistin according to EUCAST breakpoints
CRKp bacteremia: Presence of at least one set of blood culture positive for CRKp
CRKp BSI: Presence of at least one set of blood culture positive for CRKp with evidence of
systemic inflammatory response.
Index date: The day of collection of the CRKp positive blood culture, infection onset, day 0.
Active drug: Antibiotic with in vitro activity against the CRKp isolate (antibiotic which the
isolate is susceptible or intermediate to)
Inactive drug: Antibiotic without in vitro activity against the CRKp isolate (antibiotic
which the isolate is resistant to)
Empiric therapy: Treatment administered following blood culture collection and prior to
antimicrobial susceptibility test results
Targeted therapy: Treatment initiated or maintained after obtaining antimicrobial
susceptibility test results
Appropriate therapy: Treatment regimen that includes at least one active drug initiated
within 5 days of the index date and administered for at least 48 hours (24 hours for the
patients who died within 2 days of the index date)
Early appropriate therapy: Treatment regimen that includes at least one active drug initiated
within 2 days of the index date and administered for at least 48 hours (24 hours for the
patients who died within 2 days of the index date)
Inappropriate therapy: Treatment regimen that does not include any active drugs and/or
treatment administered for less than 48 h and/or treatment initiated after 5 days of the
index date.
Monotherapy: Treatment with one active drug
Combination therapy: Treatment with more than one active drug
Primary bacteremia: Catheter-related bacteremia and bacteremia of unknown source
Secondary bacteremia: Identical CRKp growth from a specific body site within BSI window
period (3 days before and 3 days after positive blood culture)
Polymicrobial bacteremia: Polymicrobial episodes (defined as ≥2 isolates of different
microorganisms in samples taken ≤2 day apart from the same patient
Suspected source: The source of bacteremia determined by the attending physician according to
the clinical presentation of the patient, rather than by the culture growth.
Source control: Central line removal, debridement, percutaneous or surgical drainage that are
performed within 48 hours of BSI onset.
VARIABLES
Host variables: Age, sex, ward (ICU or non-ICU), hospital type and ward if transferred from
another hospital, underlying diseases (Charlson Comorbidity Index), risk factors for
acquisition of CRKp (previous infection: prior positive culture with CRKp, hospital stay for
>48 hours in last three months, ICU stay for >48 hours in last three months, major surgery in
previous month, antibiotic use in last three months: Carbapenem, colistin, other, invasive
procedures performed within one week of BSI onset (insertion of central venous catheters,
nasogastric tubes, foley catheters; endoscopy; endoscopic retrograde
cholangiopancreatography; bronchoscopy; parenteral nutrition; mechanical ventilation),
disease severity at index date: SOFA score, Pitt bacteremia score, INCREMENT-CPE score,
presentation with septic shock, length of hospital stay until index date
Infection variables: Infection acquisition (Community-acquired vs. hospital-acquired),
primary or secondary bacteremia, source control, procalcitonin & C-reactive protein &
leucocyte at day 0, 7 and 14, creatinine and glomerular filtration rate (GFR).
Treatment variables: Antimicrobial therapy (duration, dosage (loading and maintenance),
presence of prolonged infusion (only for carbapenems))
Microbiological variables: Automated system used for isolate identification and antimicrobial
susceptibility testing in the local laboratory, susceptibility profile of the CRKp isolates,
MICs for carbapenem, colistin, tigecycline and ceftazidime-avibactam, carbapenemase type,
sequence type
MICROBIOLOGICAL STUDIES
Identification and antimicrobial susceptibility testing of CRKp isolates will be performed at
local laboratories. MICs will be interpreted according to EUCAST (European Committee on
Antimicrobial Susceptibility Testing) criteria. Colistin susceptibility test results will be
confirmed and ceftazidime-avibactam susceptibility results will be determined at reference
laboratory by broth microdilution. Molecular studies to identify carbapenem resistance genes,
colistin resistance mechanisms and CRKp sequence types will be performed at the reference
laboratory. Genetic relatedness of the isolates will also be determined at reference
laboratory.
STATISTICAL ANALYSIS
Survivor and non-survivor patients with CRKp bacteremia will be compared to identify
predictors of mortality. Continuous variables will be compared using t-tests or Mann-Whitney
U tests. Categorical variables will be evaluated with the χ2 or Fisher's exact test.
Two-tailed tests will be used to determine statistical significance and a p value of < 0.05
will be considered significant.
Effect of treatment type (mono vs. combination therapies, appropriate vs. inappropriate and
early vs. late start empiric and targeted therapies) on clinical or microbiological response
at day 7 (and 14 if applicable) and on mortality at day 30 will be assessed by logistic
regression and cox proportional hazards model, respectively. Independent variables that are
either identified from univariate analysis as statistically significant or reported in the
literature as being associated with the outcome will be used as covariates. Interaction
between treatment type and disease severity/mortality scores will also be assessed and
stratified analyses according to disease severity will be performed. Survival curves will be
obtained by Kaplan-Meier method and compared using log-rank test.
Propensity score for receiving combination therapy will be calculated using a logistic
regression model. Age, sex, hospital, transfer from another hospital, history of
hospitalization and antibiotic use, Charlson comorbidity index, ICU stay, SOFA score, Pitt
bacteremia score, septic shock, procalcitonin level, infection acquisition type, source of
infection will be included as independent variables in the model.
ColR CRKp cases will be compared with colistin-sensitive (ColS) controls in a nested
case-control analysis. Competing risks of death for ColR CRKp BSI will be assessed.
Discriminating ability of the models will be assessed by estimating areas under the receiver
operating characteristic (ROC) curves. Collinearity will be assessed by calculating variance
inflation factors (VIFs) for each dependent variable in the analysis. Akaike information
criteria (AIC) will be used for model selection.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03894046 -
Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex
|
Phase 3 | |
Active, not recruiting |
NCT03354338 -
Amoxicillin to Prevent Bacteria and Inflammatory Biomarkers After Intensive Periodontal Therapy
|
Phase 2 | |
Withdrawn |
NCT02543957 -
Factors Associated With Increased Risk of Bacteremia and Cholangitis in ERCP With Cholangioscopy
|
||
Completed |
NCT02210169 -
RCT of Continuous Versus Intermittent Infusion of Vancomycin in Neonates
|
N/A | |
Completed |
NCT01410578 -
The Value of sTREM-1, PCT, and CRP as Markers for the Detection of Sepsis and Bacteremia Among Patients With a FUO
|
N/A | |
Terminated |
NCT00428051 -
Colombia Epidemiologic Surveillance Study
|
N/A | |
Completed |
NCT00609375 -
Efficacy of Cefepime Continuous Infusion Versus an Intermittent Dosing Regimen
|
Phase 4 | |
Terminated |
NCT00108433 -
Linezolid in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections
|
Phase 3 | |
Completed |
NCT00177736 -
Pharmacodynamic Parameters of Two Different Doses of Cefepime
|
Phase 4 | |
Completed |
NCT00571259 -
Prophylactic Antimicrobial Catheter Lock
|
Phase 4 | |
Completed |
NCT00027248 -
Safety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-Related Bloodstream Infections
|
Phase 3 | |
Completed |
NCT05585463 -
Safety of Acupuncture and Intracutaneous Needles in Pediatric Cancer Patients: a Retrospective Study (ACUSAFE2021)
|
||
Recruiting |
NCT05950984 -
Medical Device (MD) Derived Pharmacokinetic (PK) Parameters for Vancomycin (MD-PK)
|
||
Completed |
NCT03148769 -
Spanish Bacteriemia Cohort 2016: Epidemiology, Clinical Management and Prognosis Factors
|
||
Completed |
NCT02536352 -
Effect of Supplementation of Fluoride on Maternal Periodontal Health, Preterm Delivery, and Perinatal Well-Being
|
Early Phase 1 | |
Completed |
NCT02869191 -
Blood Cultures's Profitability in Intensive Care Unit
|
||
Terminated |
NCT01734694 -
Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients
|
Phase 4 | |
Completed |
NCT01179022 -
Incidence of Bacteremia Following Argon Plasma Coagulation in Patients With Endobronchial Lesions
|
N/A | |
Recruiting |
NCT00404625 -
Infections Caused by ESbL-Producing Enterobacteriaceae in Italy
|
N/A | |
Completed |
NCT00398411 -
Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells
|
Phase 3 |